Could Hyundai Bioscience’s XAFTY become a crisis-response antiviral for Ebola and hantavirus?
Ebola urgency is rising, but broad-spectrum antivirals still face a proof gap. Hyundai Bioscience’s XAFTY now enters that debate.
Pharma & Biotech
Pharma & Biotech
Hyundai Bioscience begins U.S. Phase 2 trial of Xafty for COVID, flu, and RSV
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.